Please Wait.....
Report
Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029
Market Report I 2025-02-01 I 386 Pages I MarketsandMarkets
The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.
"Drug Discovery held the largest market share in the biosimulation market in 2023, by application."
The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.
"By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period."
By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.
"Asia Pacific is estimated to register the highest CAGR over the forecast period."
The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: Managers (40%), Directors (35%), and Others (25%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)
List of Companies Profiled in the Report:
o Certara USA. (US)
o Simulations Plus. (US)
o Dassault Systemes (France)
o Schrodinger, Inc. (US)
o Advanced Chemistry Development, Inc. (Canada)
o Chemical Computing Group ULC. (Canada)
o Rosa & Co. LLC. (US)
o Genedata AG (US)
o Physiomics Plc (United Kingdom)
o In Silico Biosciences. (US)
o Allucent. (US)
o OpenEye, Cadence Molecular Sciences. (US)
o Cellworks Group, Inc. (US)
o VeriSIM Life. (US)
o Netabolics SRL (Italy)
o Charnwood Discovery (United Kingdom)
o The MathWorks, Inc. (US)
o ANSYS, Inc (US)
o Instem Group of Companies (United Kingdom)
o Insilico Medicine (US)
o SCM - Software Chemistry & Materials (Netherlands)
o BioSymetrics, Inc. (Canada)
o Atomwise Inc. (US)
o insitro. US)
o Clinithink. (US)
Research Coverage:
This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the biosimulation market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Systemes (France), Schrodinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market. "
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKETS COVERED & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.4 CURRENCY CONSIDERED 40
1.5 STAKEHOLDERS 40
1.6 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Key data from primary sources 46
2.1.2.2 Insights from primary experts 47
2.2 MARKET SIZE ESTIMATION 48
2.3 DATA TRIANGULATION 52
2.4 MARKET SHARE ESTIMATION 53
2.5 RESEARCH ASSUMPTIONS 53
2.6 LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ASSESSMENT 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 61
4.1 BIOSIMULATION MARKET OVERVIEW 61
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023) 62
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024?2029) 63
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
5.2.1 DRIVERS 66
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 66
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies 66
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP) 67
5.2.1.4 Need to curtail drug discovery and development costs 67
5.2.1.5 Growth in biologics and biosimilars markets 67
5.2.2 RESTRAINTS 68
5.2.2.1 Lack of standardization 68
5.2.2.2 Data availability and quality 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Emerging applications 69
5.2.3.2 Use of biosimulation solutions for pediatric drug development 69
5.2.4 CHALLENGES 70
5.2.4.1 Difficulties in matching complexity of biological systems and processes 70
5.2.4.2 Shortage of biosimulation and modeling experts 70
5.3 ECOSYSTEM ANALYSIS 70
5.3.1 SOFTWARE PROVIDERS 70
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES 70
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 71
5.3.4 REGULATORY BODIES 71
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS 71
5.4 CASE STUDY ANALYSIS 72
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING 72
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER 73
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE 73
5.5 VALUE CHAIN ANALYSIS 74
5.6 PORTER'S FIVE FORCES ANALYSIS 76
5.6.1 BARGAINING POWER OF SUPPLIERS 77
5.6.2 BARGAINING POWER OF BUYERS 77
5.6.3 THREAT OF SUBSTITUTES 77
5.6.4 THREAT OF NEW ENTRANTS 77
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.7 REGULATORY ANALYSIS 78
5.7.1 REGULATORY LANDSCAPE 78
5.7.1.1 North America 78
5.7.1.2 Europe 79
5.7.1.3 Asia Pacific 79
5.7.1.4 Latin America 80
5.7.1.5 Middle East & Africa 80
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.8 PATENT ANALYSIS 83
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION 83
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 83
5.9 TECHNOLOGY ANALYSIS 84
5.9.1 KEY TECHNOLOGIES 84
5.9.1.1 Mathematical modeling 84
5.9.1.2 Software platforms 85
5.9.1.3 Quantitative systems pharmacology (QSP) 85
5.9.2 COMPLEMENTARY TECHNOLOGIES 85
5.9.2.1 Data analytics 85
5.9.2.2 Machine learning and AI 85
5.9.3 ADJACENT TECHNOLOGIES 85
5.9.3.1 In silico trials 85
5.10 INDUSTRY TRENDS 86
5.10.1 DISCOVERY OF BIOMARKERS 86
5.10.2 ADOPTION IN PERSONALIZED MEDICINE 86
5.11 PRICING ANALYSIS 86
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023 87
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE) 87
5.12 KEY CONFERENCES & EVENTS, 2024-2025 88
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 88
5.13.1 BUYING CRITERIA 89
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 90
5.15 END-USER ANALYSIS 90
5.15.1 UNMET NEEDS 90
5.15.2 END-USER EXPECTATIONS 91
5.16 INVESTMENT AND FUNDING SCENARIO 92
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 92
5.17.1 KEY USE CASES 93
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 94
5.17.2.1 Case study 94
5.17.2.2 Bioinformatics market 95
5.17.2.3 Drug discovery services market 95
5.17.2.4 Drug discovery informatics market 95
5.17.3 USER READINESS & IMPACT ASSESSMENT 95
5.17.3.1 User readiness 95
5.17.3.1.1 Pharmaceutical & biotechnology companies 95
5.17.3.1.2 Contract research organizations 96
5.17.3.2 Impact assessment 96
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies 96
5.17.3.2.1.1 Implementation 96
5.17.3.2.1.2 Impact 96
5.17.3.2.2 User B: Academic & research institutes 97
5.17.3.2.2.1 Implementation 97
5.17.3.2.2.2 Impact 97
6 BIOSIMULATION MARKET, BY OFFERING 98
6.1 INTRODUCTION 99
6.2 SOFTWARE 99
6.2.1 STANDALONE MODULES 101
6.2.1.1 Molecular modeling & simulation software 102
6.2.1.1.1 Growing importance of molecular modeling & simulation
in drug discovery and development to accelerate market growth 102
6.2.1.2 PK/PD modeling & simulation software 103
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth 103
6.2.1.3 PBPK modeling & simulation software 104
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market 104
6.2.1.4 Toxicity prediction software 105
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market 105
6.2.1.5 Clinical trial simulation software 106
6.2.1.5.1 High failure rate of clinical trials to accelerate growth 106
6.2.1.6 Other biosimulation software 107
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS 108
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms 108
6.3 SERVICES 109
6.3.1 CONSULTING & ADVISORY 111
6.3.1.1 Need to focus on core competencies to drive need for consulting
& advisory services 111
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 112
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth 112
6.3.3 DATA ANALYSIS & INTERPRETATION 113
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services 113
7 BIOSIMULATION MARKET, BY APPLICATION 114
7.1 INTRODUCTION 115
7.2 DRUG DISCOVERY 115
7.2.1 TARGET IDENTIFICATION & VALIDATION 117
7.2.1.1 Need for identification of optimal targets in drug discovery to
drive market 117
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION 118
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate
market growth 118
7.3 DRUG DEVELOPMENT 119
7.3.1 PRECLINICAL TESTING 120
7.3.1.1 PK/PD 122
7.3.1.1.1 Critical role of PK/PD studies in drug development to
drive market 122
7.3.1.2 ADME/Toxicology 123
7.3.1.2.1 Growing role in selection of potent drug molecules to
boost market growth 123
7.3.2 CLINICAL TRIALS 124
7.3.2.1 Phase I 125
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth 125
7.3.2.2 Phase II 126
7.3.2.2.1 Efficiency in dose assessment and product efficacy to
drive growth 126
7.3.2.3 Phase III 127
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand 127
7.3.2.4 Phase IV/Post-marketing surveillance 128
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption 128
7.4 DISEASE MODELING 129
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH 129
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT 130
7.5.1 PRODUCTION PLANNING & OPTIMIZATION 132
7.5.1.1 Need for proper production planning and execution to drive
market growth 132
7.5.2 QUALITY CONTROL & PROCESS MONITORING 133
7.5.2.1 Adherence to maintaining product quality to fuel market growth 133
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT 134
7.5.3.1 Need to forecast demand effectively to drive market growth 134
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING 135
7.5.4.1 Need to maintain operational continuity to support market growth 135
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS 136
7.6 OTHER APPLICATIONS 137
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 138
8.1 INTRODUCTION 139
8.2 ONCOLOGY 139
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH 139
8.3 CARDIOVASCULAR DISEASES 140
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES
TO BOOST MARKET 140
8.4 NEUROLOGICAL DISORDERS 141
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 141
8.5 INFECTIOUS DISEASES 142
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 142
8.6 OTHER THERAPEUTIC AREAS 143
9 BIOSIMULATION MARKET, BY REVENUE MODEL 145
9.1 INTRODUCTION 146
9.2 LICENSE-BASED MODELS 146
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET 146
9.3 SUBSCRIPTION-BASED MODELS 147
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 147
9.4 SERVICE-BASED MODELS 148
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS
TO SUPPORT ADOPTION 148
9.5 PAY-PER-USE MODELS 149
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH 149
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL 151
10.1 INTRODUCTION 152
10.2 ON-PREMISE MODELS 152
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 152
10.3 CLOUD-BASED MODELS 153
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD 153
10.4 HYBRID MODELS 154
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS
TO ACCELERATE ADOPTION 154
11 BIOSIMULATION MARKET, BY END USER 156
11.1 INTRODUCTION 157
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 157
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 157
?
11.3 CONTRACT RESEARCH ORGANIZATIONS 158
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 158
11.4 ACADEMIC & RESEARCH INSTITUTES 159
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH 159
11.5 REGULATORY BODIES 160
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH 160
11.6 OTHER END USERS 161
12 BIOSIMULATION MARKET, BY REGION 163
12.1 INTRODUCTION 164
12.2 NORTH AMERICA 164
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 171
12.2.2 US 171
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 171
12.2.3 CANADA 177
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market 177
12.3 EUROPE 183
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 189
12.3.2 GERMANY 189
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation 189
12.3.3 UK 195
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market 195
12.3.4 FRANCE 200
12.3.4.1 Growing R&D pipeline for clinical trials to drive market 200
12.3.5 ITALY 206
12.3.5.1 Increasing government funds and favorable regulatory scenarios
to fuel uptake 206
12.3.6 SPAIN 211
12.3.6.1 Established network of research centers to propel market 211
12.3.7 REST OF EUROPE 217
12.4 ASIA PACIFIC 222
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 229
12.4.2 CHINA 229
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market 229
12.4.3 INDIA 235
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation 235
?
12.4.4 JAPAN 241
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth 241
12.4.5 REST OF ASIA PACIFIC 246
12.5 LATIN AMERICA 251
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 257
12.5.2 BRAZIL 257
12.5.2.1 Advancing biosimulation in region to support market growth 257
12.5.3 MEXICO 262
12.5.3.1 Government initiatives to enhance digital health to propel
market growth 262
12.5.4 REST OF LATIN AMERICA 267
12.6 MIDDLE EAST & AFRICA 272
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 278
12.6.2 GCC COUNTRIES 279
12.6.2.1 Increase in healthcare investments to support market growth 279
12.6.3 REST OF MIDDLE EAST & AFRICA 284
13 COMPETITIVE LANDSCAPE 291
13.1 INTRODUCTION 291
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 291
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET 292
13.3 REVENUE ANALYSIS, 2019-2023 293
13.4 MARKET SHARE ANALYSIS, 2023 293
13.5 RANKING OF KEY MARKET PLAYERS 296
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 296
13.6.1 STARS 297
13.6.2 EMERGING LEADERS 297
13.6.3 PERVASIVE PLAYERS 297
13.6.4 PARTICIPANTS 297
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 299
13.6.5.1 Company footprint 299
13.6.5.2 Offering footprint 300
13.6.5.3 Application footprint 301
13.6.5.4 End-user footprint 302
13.6.5.5 Region footprint 303
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023 304
13.7.1 PROGRESSIVE COMPANIES 304
13.7.2 RESPONSIVE COMPANIES 304
13.7.3 DYNAMIC COMPANIES 304
13.7.4 STARTING BLOCKS 304
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 306
13.8 COMPANY EVALUATION AND FINANCIAL METRICS, 2025 308
13.9 BRAND/PRODUCT COMPARISON 309
13.10 COMPETITIVE SCENARIO 310
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 310
13.10.2 DEALS 311
13.10.3 EXPANSIONS 312
13.10.4 OTHER DEVELOPMENTS 312
14 COMPANY PROFILES 313
14.1 KEY PLAYERS 313
14.1.1 CERTARA, USA 313
14.1.1.1 Business overview 313
14.1.1.2 Products & services offered 314
14.1.1.3 Recent developments 316
14.1.1.3.1 Product launches & enhancements 316
14.1.1.3.2 Deals 318
14.1.1.3.3 Other developments 319
14.1.1.4 MnM view 319
14.1.1.4.1 Right to win 319
14.1.1.4.2 Strategic choices 319
14.1.1.4.3 Weaknesses & competitive threats 319
14.1.2 DASSAULT SYSTEMES 320
14.1.2.1 Business overview 320
14.1.2.2 Products & services offered 321
14.1.2.3 Recent developments 322
14.1.2.3.1 Product launches & enhancements 322
14.1.2.3.2 Deals 323
14.1.2.3.3 Other developments 323
14.1.2.4 MnM view 324
14.1.2.4.1 Right to win 324
14.1.2.4.2 Strategic choices 324
14.1.2.4.3 Weaknesses & competitive threats 324
14.1.3 SCHRODINGER, INC. 325
14.1.3.1 Business overview 325
14.1.3.2 Products & services offered 326
14.1.3.3 Recent developments 328
14.1.3.3.1 Deals 328
14.1.3.3.2 Other developments 329
14.1.3.4 MnM view 330
14.1.3.4.1 Right to win 330
14.1.3.4.2 Strategic choices 330
14.1.3.4.3 Weaknesses & competitive threats 330
14.1.4 SIMULATIONS PLUS 331
14.1.4.1 Business overview 331
14.1.4.2 Products & services offered 332
14.1.4.3 Recent Developments 336
14.1.4.3.1 Product Launches & Enhancements 336
14.1.4.3.2 Deals 337
14.1.4.3.3 Other developments 339
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. 340
14.1.5.1 Business overview 340
14.1.5.2 Products & Services Offered 340
14.1.5.3 Recent developments 341
14.1.5.3.1 Product launches & enhancements 341
14.1.5.3.2 Deals 341
14.1.6 CHEMICAL COMPUTING GROUP ULC 342
14.1.6.1 Business overview 342
14.1.6.2 Products & services offered 342
14.1.6.3 Recent developments 343
14.1.6.3.1 Product launches & enhancements 343
14.1.6.3.2 Deals 343
14.1.6.3.3 Other developments 343
14.1.7 ROSA & CO. LLC 344
14.1.7.1 Business overview 344
14.1.7.2 Products & services offered 344
14.1.8 GENEDATA AG (A DANAHER COMPANY) 345
14.1.8.1 Business overview 345
14.1.8.2 Products & services offered 346
14.1.8.3 Recent developments 347
14.1.8.3.1 Product launches & enhancements 347
14.1.8.3.2 Deals 347
14.1.9 PHYSIOMICS PLC 348
14.1.9.1 Business overview 348
14.1.9.2 Products & services offered 349
14.1.9.3 Recent developments 350
14.1.9.3.1 Product launches & enhancements 350
14.1.9.3.2 Other developments 350
14.1.10 IN SILICO BIOSCIENCES 351
14.1.10.1 Business overview 351
14.1.10.2 Products & services offered 351
14.1.11 ALLUCENT 352
14.1.11.1 Business overview 352
14.1.11.2 Products & services offered 352
?
14.1.11.3 Recent developments 353
14.1.11.3.1 Deals 353
14.1.11.3.2 Expansions 353
14.1.11.3.3 Other developments 353
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES 354
14.1.12.1 Business overview 354
14.1.12.2 Products & services offered 355
14.1.12.3 Recent developments 356
14.1.12.3.1 Product enhancements 356
14.1.12.3.2 Deals 356
14.1.12.3.3 Expansions 357
14.1.13 CELLWORKS GROUP, INC. 358
14.1.13.1 Business overview 358
14.1.13.2 Products & services offered 358
14.1.13.3 Recent developments 359
14.1.13.3.1 Other developments 359
14.1.14 VERISIM LIFE 360
14.1.14.1 Business overview 360
14.1.14.2 Products & services offered 360
14.1.14.3 Recent developments 361
14.1.14.3.1 Deals 361
14.1.14.3.2 Other developments 362
14.1.15 NETABOLICS 363
14.1.15.1 Business overview 363
14.1.15.2 Products & services offered 363
14.1.16 CHARNWOOD DISCOVERY 364
14.1.16.1 Business overview 364
14.1.16.2 Products & services offered 364
14.1.16.3 Recent developments 365
14.1.16.3.1 Deals 365
14.1.17 THE MATHWORKS, INC. 366
14.1.17.1 Business overview 366
14.1.17.2 Products & services offered 366
14.1.17.3 Recent developments 367
14.1.17.3.1 Product enhancements 367
14.1.18 ANSYS, INC. 368
14.1.18.1 Business overview 368
14.1.18.2 Products & services offered 369
14.1.18.3 Recent developments 369
14.1.18.3.1 Deals 369
14.1.18.3.2 Other developments 370
?
14.2 START-UP/SME PLAYERS 371
14.2.1 INSTEM GROUP OF COMPANIES 371
14.2.2 INSILICO MEDICINE 372
14.2.3 SCM - SOFTWARE CHEMISTRY & MATERIALS 373
14.2.4 BIOSYMETRICS, INC. 373
14.2.5 ATOMWISE INC. 374
14.2.6 INSITRO 374
14.2.7 CLINITHINK 375
15 APPENDIX 376
15.1 DISCUSSION GUIDE 376
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 382
15.3 CUSTOMIZATION OPTIONS 384
15.4 RELATED REPORTS 384
15.5 AUTHOR DETAILS 385
TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM 71
TABLE 2 BIOSIMULATION MARKET: PORTER'S FIVE FORCES 76
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING 87
TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024-2025 88
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 89
TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 89
TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET 90
TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET 91
TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 99
TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 100
TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 100
TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 101
TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY,
2022-2029 (USD MILLION) 102
TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION
SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION) 103
TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE,
BY COUNTRY, 2022-2029 (USD MILLION) 104
TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE,
BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION) 106
TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE,
BY COUNTRY, 2022-2029 (USD MILLION) 107
TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE,
BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS,
BY COUNTRY, 2022-2029 (USD MILLION) 109
TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 110
TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES,
BY COUNTRY, 2022-2029 (USD MILLION) 111
TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES,
BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 115
TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE,
2022-2029 (USD MILLION) 116
TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION,
BY COUNTRY, 2022-2029 (USD MILLION) 117
TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION,
BY COUNTRY, 2022-2029 (USD MILLION) 118
TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 119
TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 121
TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY,
2022-2029 (USD MILLION) 121
TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY,
2022-2029 (USD MILLION) 123
TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 124
TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY,
2022-2029 (USD MILLION) 125
TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY,
2022-2029 (USD MILLION) 126
TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY,
2022-2029 (USD MILLION) 127
TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY,
2022-2029 (USD MILLION) 128
TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE,
BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 130
TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 131
TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION,
BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING,
BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022-2029 (USD MILLION) 135
TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2022-2029 (USD MILLION) 137
TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 139
TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY,
2022-2029 (USD MILLION) 140
TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2022-2029 (USD MILLION) 141
TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY,
2022-2029 (USD MILLION) 142
TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2022-2029 (USD MILLION) 143
TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,
2022-2029 (USD MILLION) 144
TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION) 146
TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 147
TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION) 148
TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 149
TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 150
TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION) 152
TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 153
TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 154
TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY,
2022-2029 (USD MILLION) 155
TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 157
TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION) 158
TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY,
2022-2029 (USD MILLION) 161
TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY,
2022-2029 (USD MILLION) 162
TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022-2029 (USD MILLION) 164
TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 165
TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 166
TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 166
TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 166
TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 167
TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 167
TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 167
TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 168
TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION) 168
TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 168
TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 169
TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 169
TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 170
TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 170
TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 170
TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 172
TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 172
TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 172
TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 173
TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 173
TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 173
TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 174
TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 174
TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 174
TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 175
TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 175
TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION) 176
TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 176
TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 176
TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 177
TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 177
TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 178
TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 178
TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 179
TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 179
TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 179
TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 180
TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 180
TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 181
TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 181
TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 182
TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 182
TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 182
TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 183
TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 184
TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 184
TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 185
TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 185
TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 185
TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 186
TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 186
TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 186
TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 187
TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 187
TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 188
TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 188
TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 188
TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 190
TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 190
TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 190
TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 191
TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 191
TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 191
TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 192
TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 192
TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 192
TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 193
TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 193
TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 194
TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 194
TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 194
TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 195
TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 195
TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 196
TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 196
TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 197
TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 197
TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 197
TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 198
TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 198
TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 198
TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 199
TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION) 199
TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 199
TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 200
TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 201
TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 201
TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 201
TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 202
TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 202
TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 202
TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 203
TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 203
TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 203
TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 204
TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 204
TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 205
TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 205
TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 205
TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 206
TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 206
TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 207
TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 207
TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 208
TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 208
TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 208
TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 209
TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 209
TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 209
TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 210
TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION) 210
TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 210
TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 211
TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 212
TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 212
TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 212
TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 213
TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 214
TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 214
TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 214
TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 215
TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 215
TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 216
TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 216
TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 216
TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 217
TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 217
TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 218
TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 218
TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 219
TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 219
TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022-2029 (USD MILLION) 220
TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS,
BY TYPE, 2022-2029 (USD MILLION) 220
TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 220
TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 221
TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 221
TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 221
TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 222
TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 224
TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 224
TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 224
TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 225
TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 225
TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 225
TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION) 226
TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 227
TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 227
TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 228
TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 228
TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 228
TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 229
TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 230
TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 230
TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 231
TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 231
TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 231
TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 232
TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 232
TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 232
TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 233
TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 233
TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 234
TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 234
TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 234
TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 235
TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 236
TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 236
TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 236
TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 237
TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 237
TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 237
TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 238
TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 238
TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 238
TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 239
TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 239
TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION) 240
TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 240
TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 240
TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 241
TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION) 241
TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 242
TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 242
TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 242
TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 243
TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 243
TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 244
TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 244
TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 245
TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 245
TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 245
TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 246
TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 246
TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 247
TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 247
TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 247
TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 248
TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 248
TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 248
TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022-2029 (USD MILLION) 249
TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION) 249
TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 249
TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 250
TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 250
TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 250
TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 251
TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 251
TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 252
TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 252
TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 252
TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 253
TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 253
TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 253
TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 254
TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION) 254
TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 254
TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 255
TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 255
TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 256
TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 256
TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 256
TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 257
TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 258
TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 258
TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION) 258
TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 259
TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 259
TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 259
TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 260
TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 260
TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 260
TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 261
TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 261
TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 261
TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 262
TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION) 262
TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 263
TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE,
2022-2029 (USD MILLION) 263
TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 263
TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 264
TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 264
TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS,
BY TYPE, 2022-2029 (USD MILLION) 264
TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE,
2022-2029 (USD MILLION) 265
TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE,
2022-2029 (USD MILLION) 265
TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 265
TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 266
TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 266
TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 266
TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION) 267
TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 267
TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 268
TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION) 268
TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 268
TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 269
TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 269
TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 269
TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022-2029 (USD MILLION) 270
TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS,
BY TYPE, 2022-2029 (USD MILLION) 270
TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING
& SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE,
2022-2029 (USD MILLION) 270
TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 271
TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 271
TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION) 271
TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 272
TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 273
TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 273
TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 273
TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE
MODULES, BY TYPE, 2022-2029 (USD MILLION) 274
TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 274
TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 275
TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS,
BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING
& SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE,
2022-2029 (USD MILLION) 276
TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 277
TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 277
TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION) 277
TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 278
TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 279
TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE,
2022-2029 (USD MILLION) 279
TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES,
BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE,
2022-2029 (USD MILLION) 280
TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION,
2022-2029 (USD MILLION) 281
TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY
APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 281
TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 281
TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING,
BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS,
BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 282
TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 283
TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL,
2022-2029 (USD MILLION) 283
TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL,
2022-2029 (USD MILLION) 283
TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER,
2022-2029 (USD MILLION) 284
TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2022-2029 (USD MILLION) 285
TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET,
BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET,
BY TYPE, 2022-2029 (USD MILLION) 286
TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION) 286
TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION) 287
TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL
TRIALS, BY TYPE, 2022-2029 (USD MILLION) 288
TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR
MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE,
2022-2029 (USD MILLION) 288
TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 289
TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE
MODEL, 2022-2029 (USD MILLION) 289
TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET,
BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION) 289
TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET,
BY END USER, 2022-2029 (USD MILLION) 290
TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET 292
TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION 294
TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT 300
TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT 301
TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT 302
TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT 303
TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES 306
TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY
EMERGING PLAYERS/STARTUPS 307
TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2021-JANUARY 2025 310
TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021- JANUARY 2025 311
TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021- JANUARY 2025 312
TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS,
JANUARY 2021- JANUARY 2025 312
TABLE 404 CERTARA, USA: COMPANY OVERVIEW 313
TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED 314
TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021?JANUARY 2025 316
TABLE 407 CERTARA, USA: DEALS, JANUARY 2021?JANUARY 2025 318
TABLE 408 CERTARA, USA: OTHER DEVELOPMENTS, JANUARY 2021?JANUARY 2025 319
TABLE 409 DASSAULT SYSTEMES: COMPANY OVERVIEW 320
TABLE 410 DASSAULT SYSTEMES: PRODUCTS & SERVICES OFFERED 321
TABLE 411 DASSAULT SYSTEMES: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2021? JANUARY 2025 322
TABLE 412 DASSAULT SYSTEMES: DEALS, JANUARY 2021?JANUARY 2025 323
TABLE 413 DASSAULT SYSTEMES: OTHER DEVELOPMENTS, JANUARY 2021?JANUARY 2025 323
TABLE 414 SCHRODINGER, INC.: COMPANY OVERVIEW 325
TABLE 415 SCHRODINGER, INC.: PRODUCTS & SERVICES OFFERED 326
TABLE 416 SCHRODINGER, INC.: DEALS, JANUARY 2021?JANUARY 2025 328
TABLE 417 SCHRODINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2021?JANUARY 2025 329
TABLE 418 SIMULATIONS PLUS: COMPANY OVERVIEW 331
TABLE 419 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED 332
TABLE 420 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021?JANUARY 2025 336
TABLE 421 SIMULATIONS PLUS: DEALS, JANUARY 2021?JANUARY 2025 337
TABLE 422 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 339
TABLE 423 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW 340
TABLE 424 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED 340
TABLE 425 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES
& ENHANCEMENTS, JANUARY 2021?JANUARY 2025 341
TABLE 426 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS,
JANUARY 2021?JANUARY 2025 341
TABLE 427 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW 342
TABLE 428 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED 342
TABLE 429 CHEMICAL COMPUTING GROUP ULC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021?JANUARY 2025 343
TABLE 430 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021?JANUARY 2025 343
TABLE 431 CHEMICAL COMPUTING GROUP ULC: OTHER DEVELOPMENTS, JANUARY 2021?JANUARY 2025 343
TABLE 432 ROSA & CO. LLC: COMPANY OVERVIEW 344
TABLE 433 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED 344
TABLE 434 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW 345
TABLE 435 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED 346
TABLE 436 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021?JANUARY 2025 347
TABLE 437 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021?JANUARY 2025 347
TABLE 438 PHYSIOMICS PLC: COMPANY OVERVIEW 348
TABLE 439 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED 349
TABLE 440 PHYSIOMICS PLC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021?JANUARY 2025 350
TABLE 441 PHYSIOMICS PLC: OTHER DEVELOPMENTS, JANUARY 2021?JANUARY 2025 350
TABLE 442 IN SILICO BIOSCIENCES: COMPANY OVERVIEW 351
TABLE 443 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED 351
TABLE 444 ALLUCENT: COMPANY OVERVIEW 352
TABLE 445 ALLUCENT: PRODUCTS & SERVICES OFFERED 352
TABLE 446 ALLUCENT: DEALS, JANUARY 2021?JANUARY 2025 353
TABLE 447 ALLUCENT: EXPANSIONS, JANUARY 2021- JANUARY 2025 353
TABLE 448 ALLUCENT: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 353
TABLE 449 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW 354
TABLE 450 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED 355
TABLE 451 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021?JANUARY 2025 356
TABLE 452 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY
2021?JANUARY 2025 356
TABLE 453 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS,
JANUARY 2021- JANUARY 2025 357
TABLE 454 CELLWORKS GROUP, INC.: COMPANY OVERVIEW 358
TABLE 455 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED 358
TABLE 456 CELLWORKS GROUP, INC.: OTHER DEVELOPMENTS,
JANUARY 2021-JANUARY 2025 359
TABLE 457 VERISIM LIFE: COMPANY OVERVIEW 360
TABLE 458 VERISIM LIFE: PRODUCTS & SERVICES OFFERED 360
TABLE 459 VERISIM LIFE: DEALS, JANUARY 2021?JANUARY 2025 361
TABLE 460 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 362
TABLE 461 NETABOLICS: COMPANY OVERVIEW 363
TABLE 462 NETABOLICS: PRODUCTS & SERVICES OFFERED 363
TABLE 463 CHARNWOOD DISCOVERY: COMPANY OVERVIEW 364
TABLE 464 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED 364
TABLE 465 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021?JANUARY 2025 365
TABLE 466 THE MATHWORKS, INC.: COMPANY OVERVIEW 366
TABLE 467 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED 366
TABLE 468 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS,
JANUARY 2021?JANUARY 2025 367
TABLE 469 ANSYS, INC.: COMPANY OVERVIEW 368
TABLE 470 ANSYS, INC.: PRODUCTS & SERVICES OFFERED 369
TABLE 471 ANSYS, INC.: DEALS, JANUARY 2021?JANUARY 2025 369
TABLE 472 ANSYS, INC.: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025 370
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security